Laurus Labs (LAURUSLABS) Fundamentals 2026 — P/E 95.9x, Revenue Analysis | SniperIQ
Laurus Labs (LAURUSLABS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹85,246 Crore, trading at ₹1577.65 on the BSE. This SniperIQ fundamentals page covers Laurus Labs's valuation (P/E 95.9x, P/B 16.1x), profitability (net margin 13.0%), revenue (₹6,813 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Laurus Labs's market cap?
Laurus Labs (LAURUSLABS) has a market capitalization of approximately ₹85,246 Crore, trading at ₹1577.65 on the BSE. Market cap moves with the live share price.
What is Laurus Labs's P/E ratio?
Laurus Labs's trailing twelve-month P/E ratio is 95.9x, with a price-to-book (P/B) of 16.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Laurus Labs?
Laurus Labs runs a net profit margin of 13.0%, a gross margin of 45.1%, and an operating margin of 25.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Laurus Labs generate?
Laurus Labs reported revenue of ₹6,813 Crore for fiscal year 2026, with net income of ₹889 Crore and earnings per share (EPS) of 16.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Laurus Labs pay a dividend?
Laurus Labs offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Laurus Labs financially healthy?
Laurus Labs carries a debt-to-equity ratio of 0.48x and a current ratio of 1.33x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Laurus Labs a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Laurus Labs (LAURUSLABS) the key facts are: market cap ₹85,246 Crore, P/E 95.9x, revenue ₹6,813 Crore, 52-week range 810.75-1599.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Laurus Labs's full fundamentals live
Get Laurus Labs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.